Context Therapeutics Inc (CNTX)

Piper Sandler Companies Initiates Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World

Defense World

Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at HC Wainwright - Defense World

Defense World

Context Therapeutics Inc (CNTX)'s Ratio Roundup: Key Metrics for Trailing Twelve Months – DWinneX - The Dwinnex

The Dwinnex

Context Therapeutics (NASDAQ:CNTX) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat

MarketBeat

Piper Sandler bullish on Context Therapeutics stock, cites CTIM-76 program - Investing.com Canada

Investing.com Canada

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

MyChesCo

Galera Therapeutics Explores Strategic Options Amid Financial Results Announcement - MyChesCo

MyChesCo

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why - Yahoo Canada Finance

Yahoo Canada Finance

Here's What Bronte Capital Calls “Sarepta Risk” in the Context of Sarepta Therapeutics (SRPT) - Yahoo New Zealand News

Yahoo New Zealand News

StockNews.com Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) to Sell - Defense World

Defense World

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $95.00 by Analysts at Oppenheimer - Defense World

Defense World

Context Therapeutics (NASDAQ:CNTX) PT Raised to $10.00 - Defense World

Defense World

Context Therapeutics (NASDAQ:CNTX) PT Raised to $5.00 - Defense World

Defense World

NRx Pharmaceuticals Makes Significant Stride with New Depression Drug, Aims for Accelerated FDA Approval - MyChesCo

MyChesCo

Context Therapeutics Inc. (NASDAQ:CNTX) Sees Large Drop in Short Interest - MarketBeat

MarketBeat

Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 - MyChesCo

MyChesCo

Context Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug Trials - MyChesCo

MyChesCo

Context Therapeutics Inc (CNTX)'s Ratio Roundup: Key Metrics for Trailing Twelve Months – DWinneX - The Dwinnex

The Dwinnex

A Look at Context Therapeutics Inc (CNTX) Shares in the Recent Past Indicates Growth – Sete News - SETE News

SETE News

Madrigal's Pioneering NASH Treatment Receives FDA Approval, Raises $690 Million in Funding - MyChesCo

MyChesCo

Madrigal's Pioneering NASH Treatment Receives FDA Approval, Raises $690 Million in Funding - MyChesCo

MyChesCo

Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo

MyChesCo

Context Therapeutics stock target raised on trial update - Investing.com Canada

Investing.com Canada

Windtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement - MyChesCo

MyChesCo

Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo

MyChesCo

Essential Utilities Reports Optimistic Q1 2024 Results Despite Warmer Weather - MyChesCo

MyChesCo

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results - GlobeNewswire

GlobeNewswire

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results - Yahoo Finance

Yahoo Finance

Zenas' $200m round heads big clutch of bio financings - pharmaphorum

pharmaphorum

Virpax Pharmaceuticals' Probudur Shows Promising Results in Pain Management Study - MyChesCo

MyChesCo

Context Therapeutics gets FDA approval for clinical trials of cancer drug - Pennsylvania Business Report - Pennsylvania Business Report

Pennsylvania Business Report

FDA accepts BLA for subcutaneous nivolumab in solid tumors - Urology Times

Urology Times

FDA accepts BLA for subcutaneous nivolumab in solid tumors - Urology Times

Urology Times

Wistar Institute Unveils New Strategies to Fight Glioblastoma, A Deadly Brain Cancer - MyChesCo

MyChesCo

Context's CTIM-76 cleared to enter clinic for CLDN6-positive cancers - BioWorld Online

BioWorld Online

FDA Clears Context Therapeutics to Begin Trial for Novel Cancer Therapy - MyChesCo

MyChesCo

Public equity report: Soleno, Abeona raise capital for late-stage rare disease programs - BioCentury

BioCentury

Context Therapeutics Secures $100 Million in Private Placement to Fuel Clinical Trials - MyChesCo

MyChesCo

Context Therapeutics Announces $100 Million Private Placement - GlobeNewswire

GlobeNewswire

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

GlobeNewswire Inc.

Context Therapeutics stock jumps on $100M private placement (NASDAQ:CNTX) - Seeking Alpha

Seeking Alpha

Ferring Pharmaceuticals Partners with SK pharmteco to Boost Gene Therapy Supply - MyChesCo

MyChesCo

NCCN Foundation Announces 2024 Young Investigator Award Recipients in Cancer Research - MyChesCo

MyChesCo

Ocugen's Leap into Phase 3 Trials: A Beacon of Hope for Retinitis Pigmentosa Patients - MyChesCo

MyChesCo

13 Biotech Companies In Philadelphia To Know - Built In

Built In

Context Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer Therapy - MyChesCo

MyChesCo

Context Therapeutics files IND application for CTIM-76 for CLDN6-positive gynecologic and testicular cancers - BioWorld Online

BioWorld Online

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

GlobeNewswire Inc.

Context Therapeutics Advances Cancer Trial with FDA Submission - TipRanks.com - TipRanks

TipRanks

FDA Clearance Paves Way for Aprea Therapeutics' Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial - MyChesCo

MyChesCo